Clinical Trials Document Epilepsy Safety 
Cannabis Law Report
DECEMBER 7, 2021
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.
The Joint Blog
JANUARY 12, 2020
Passage of the 2018 Farm Bill, which eased federal legal restrictions on hemp cultivation and transport, unleashed a stampede of companies rushing products to the market in an absence of regulations ensuring safety, quality and effectiveness. Still, scientific documentation of CBD’s safety and efficacy is nearly nonexistent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healer
DECEMBER 17, 2021
The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Epilepsy & behavior case reports 9 (2018): 10. Alsherbiny, Muhammad, and Chun Li. Medicines 6.1
Healer
DECEMBER 17, 2021
The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Epilepsy & behavior case reports 9 (2018): 10. [4] Drug metabolism reviews 46.1 2014): 86-95. [2] Medicines 6.1
Cannabis Law Report
OCTOBER 26, 2019
One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.
Cannabis Law Report
DECEMBER 28, 2021
We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax has acquired the exclusive worldwide rights from Nanomerics to use its MET platform for the nasal delivery of CBD for the management of epilepsy in children (a rare pediatric disease) and adults.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Refractory paediatric epilepsy. At the same time, the outlook on cannabis research data is largely positive. Conclusions.
Expert insights. Personalized for you.
52 
Let's personalize your content